Abstract
Stage IV small cell lung cancer (SCLC) has a median survival of less than 12 months, but rates of long term survival remain unclear. The importance of understanding long term survival increased recently with studies demonstrating improved survival with immune checkpoint inhibitors plus standard chemotherapy. We pursued an analysis of real world outcomes of patients in the province of Manitoba, Canada with stage IV SCLC treated with platinum-etoposide chemotherapy to clarify the likelihood of long term survival and predictive factors.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
